Crescendo Biologics Appoints Theodora Harold as Chief Financial Officer View PDF

Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m View PDF

Crescendo strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody^® therapeutics. View PDF

Key Oncology Data on Humabody^® Drug Conjugates. View PDF

Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property. View PDF